Why Participate in our trials?
Clinical trials study whether or not new medicines, devices, or diagnostic techniques work and are safe for use. Patients choose to participate in clinical trials for a variety of reasons such as a desire to contribute to the greater good through science or access to cutting edge treatments. By participating in clinical trials they are frequently seen by highly trained experts in their field. Compensation for time and effort is sometimes offered for trial participation.
Clinical trials are carefully planned and meticulously reviewed by groups of health specialists called Institutional Review Boards. Patients participate exclusively as volunteers for studies and enroll only after a detailed informed consent process. Patient volunteers have the right to drop out of a trial at any time.
CURRENTLY ENROLLING
COPD
Idiopathic Pulmonary Fibrosis
Asthma
Bronchiectasis
For more information on trials or to ask questions contact us here.
COPD
Genentech GB43311
Research Trial
A Phase 2b study to evaluate the efficacy, safety, and pharmacokinetics of Astegolimab compared to placebo in patients with COPD who are former or current smokers and have a history of frequent exacerbations. Subjects will receive subcutaneous injections every 2 weeks thru week 52. Subjects must have 2 or more exacerbations within a 24-month period of time.
Idiopathic Pulmonary Fibrosis
Pulse
Research Trial
A Phase 3 study to assess pulsed, inhaled nitric oxide in patients with IPF/ILD on long-term oxygen. Inhaled nitric oxide is delivered with oxygen using an investigational device for patients with IPF/other ILD currently on supplemental O2 who may or may not be using background therapies. Must have FVC > 40%. Blinded treatment period is 16 weeks. Patients will be offered open-label therapy after completing blinded treatment period.
Idiopathic Pulmonary Fibrosis
Pliant
Research Trial
Randomized, Double-Blind, Placebo-Controlled Phase 2a trial evaluating safety, tolerability and pharmacokinetics of PLN-74809 in participants with patients diagnosed with IPF. Oral tablet administered daily for 12 weeks. IPF diagnosis up to 5 years. SOC is allowed if stable for 3 months.
Idiopathic Pulmonary Fibrosis
United Therapeutics
Research Trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety fo Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis over a 52 week period. Subjects will be randomly assigned 1:1 to inhaled treprostinil or placebo at Baseline. All subjects will initiate inhaled treprostinil (6 mcg/breath) or placebo at a dose of 3 breaths (18 mcg) administered QID (during waking hours) and will titrate to a target dosing regimen for 12 breaths (72 mcg) QID. Standard of care (SOC) background therapy for IPF with either nintedanib or pirfenidone will be allowed.
Idiopathic Pulmonary Fibrosis
Roche
Research Trial
A Phase III Randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis during a 52-week period. Subjects will receive 10 mg/kg PRM-151 vs. placebo every 4 weeks via (IV) infusion. Standard of care treatment is allowed. Open-label extension opportunity is available at the end of the 52-week period.
Asthma
GSK
Research Trial
A 52-week study to evaluate the efficacy of GSK3511294 100mg (SC) every 26 weeks versus maintaining existing treatment with either mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype who have previously benefited from anti-IL-5/5R therapy. Subjects either need to be on Fasenra or Nucala for 12 months prior to study start. Subjects will be randomized to either their current medication or GSK3511294.
We are not currently enrolling for Interstitial Lung Disease trials, but we are constantly reviewing new studies for future enrollment.
If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.
Bronchiectasis
Zambon SpA
Z7224L02/Promis II
Research Trial
A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTRE, CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF 12 MONTHS OF THERAPY WITH INHALED COLISTIMETHATE SODIUM IN THE TREATMENT OF SUBJECTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA (P. AERUGINOSA)
Purpose: The primary objective of the trial is to investigate the effect of the use of inhaled colistimethate sodium, administered twice daily via the I-neb for 12 months, compared to placebo in subjects with non–cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa on the frequency of pulmonary exacerbations.
We are not currently enrolling for PE/DVT trials, but we are constantly reviewing new studies for future enrollment.
If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.
We are not currently enrolling for Pulmonary Hypertension trials, but we are constantly reviewing new studies for future enrollment.
If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.